Trial reportmSphere2020
Genetic Association Reveals Protection against Recurrence of
Trial report in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Pooled it
- Environmental and Nutritional Parameters Modulating Genetic Expression for Virulence Factors ofAntibiotics (Basel, Switzerland) · 2024Review
- Genetic variation in the human leukocyte antigen region confers susceptibility to Clostridioides difficile infection.Scientific reports · 2023Article
- AWOT and CWOT for genotype and genotype-by-treatment interaction joint analysis in pharmacogenetics GWAS.Bioinformatics (Oxford, England) · 2023Article
- The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review.Cureus · 2022Review
- Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQβ1.American journal of human genetics · 2022Article
- Translational Aspects of the Immunology of Clostridioides difficile Infection: Implications for Pediatric Populations.Journal of the Pediatric Infectious Diseases Society · 2021Review
- Host Immune Responses toFrontiers in microbiology · 2021Review
- Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies.Infectious diseases and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bezlotoxumab is a human monoclonal antibody against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.